GlassScriptPhysician profile
Danielle L Blackard
NPI 1013458694
$18,827.21
in general payments reported to CMS, 2019-2025
23 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,733 · 2022: $1,597 · 2023: $6,062 · 2024: $9,322 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,650 · Travel and Lodging: $5,037 · Food and Beverage: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,650.00 |
| Travel and Lodging | $5,036.57 |
| Food and Beverage | $810.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $15,298.00 | 2021-2024 | Epclusa |
| Abbvie INC. | $970.72 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $706.94 | 2021-2023 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $478.49 | 2021-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $398.39 | 2021-2022 | |
| Evoke Pharma, INC. | $188.51 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $110.46 | 2022 | |
| Celgene Corporation | $109.88 | 2021-2023 | Zeposia |
| Pfizer INC. | $104.27 | 2021-2023 | |
| Braintree Laboratories, INC. | $77.00 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $52.99 | 2024 | Voquezna |
| Genzyme Corporation | $49.68 | 2022 | |
| Ironwood Pharmaceuticals, INC | $47.02 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $38.03 | 2021-2023 | |
| Ardelyx, INC. | $36.51 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $30.51 | 2021-2022 | |
| Redhill Biopharma INC. | $29.43 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $18.47 | 2021 | |
| Qol Medical, LLC | $18.01 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $17.88 | 2022 | |
| Neurocrine Biosciences, INC. | $17.32 | 2022 | |
| Boston Scientific Corporation | $16.53 | 2023 | |
| Intercept Pharmaceuticals, INC. | $12.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Blackard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.